Skip to main content

Resverlogix Corp(RVX-T)
TSX

Today's Change
Real-Time Last Update

Resverlogix: Top 10 Undervalued Biotechnology Industry Stocks on TSE (RVX)

The Globe and Mail - Sun Sep 18, 2022
Industry Group

Resverlogix is now ranked among the top 10 undervalued stocks in the Biotechnology industry on the Toronto Stock Exchange. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company. Valuation methodology provided by Stockcalc (see below).

Biotechnology: Biotech and biopharmaceutical companies engaged in research, discovery, development, and production of innovative drug and drugrelated technologies. Stocks in this category are held primarily for capital appreciation.

SymbolNameClose Price ($)Valuation ($)DifferenceAverage Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
RVX-TResverlogix0.230.350.11
(48.01)
25,10658.600
APS-TAptose Biosciences0.892.711.82
(204.05)
15,86982.100
REUN-TReunion Neuroscience3.325.522.2
(66.4)
19,46338.600
AEZS-TAEterna Zentaris6.1610.994.83
(78.37)
2,22429.900
APLI-TAppili Therapeutics0.060.110.05
(75.47)
87,1715.500
MBX-TMicrobix Biosystems0.530.660.13
(25.19)
39,53976026.5
MDNA-TMedicenna Therapeutics1.141.310.17
(14.56)
58,8376400
HBP-THelix BioPharma0.260.310.05
(20.83)
25,37937.600
BCT-TBriaCell Therapeutics10.918.357.45
(68.32)
6,558167.400
IPCI-TIntelliPharmaCeutics Intl0.110.220.11
(95.96)
3,1653.600

More about Resverlogix

All data provided as-at market close September 15, 2022. The list is sorted by stocks with the greatest percentage difference between valuation and price. Resverlogix Resverlogix Corp is a clinical stage biotechnology company. It is engaged in developing RVX-208, a molecule selective inhibit BET domain inhibitor for the treatment of patients with cardiovascular, diabetes mellitus, Alzheimer's & chronic kidney disease. Resverlogix is listed under RVX on the Toronto Stock Exchange.

Artificial intelligence at Report on Business

Artificial Intelligence at Report on Business Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.

More from The Globe